Response of morphology and pro-inflammatory molecules in the prostate anterior lobe after Nintedanib therapy in TRAMP mice

• Grant number: 15/16747-3
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: October 01, 2015
• End date: March 31, 2017
• Field of knowledge: Biological Sciences - Morphology - Cytology and Cell Biology
• Principal Investigator: Valéria Helena Alves Cagnon Quitete
• Grantee: Letícia Ferreira Alves
• Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

Prostate cancer is the sixth most common type of cancer in the world and the most prevalent in men, considering the aging process. Different studies of prostate lesions, including its prevention and treatment, have been evaluated. The antiangiogenic drugs with antiproliferative properties such as Nintedanib (BIBF-1120) have received special attention due to positive results in the prostate cancer prevention and treatment. The aim of study herein is to evaluate the Nintedanib therapy effects on the morphology and in molecules involved in the inflammatory process in the prostate anterior lobe in distinct periods of the tumor development in TRAMP mice. Animals will be treated with Nintedanib at a dose of 10mg/kg/day in inicial and intermediate stages of tumoral development, corresponding to prostatic lesions in 12 and 16 week old mice. At the end of the treatment, the prostate anterior lobe will be collected and submitted to structural and IL-17 and COX-2 immunohistochemical analysis.

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

ALVES, LETCIA FERREIRA; DA SILVA, RAQUEL FRENEDOSO; ALVES CAGNON, VALERIA HELENA. Nintedanib effects on delaying cancer progression and decreasing COX-2 and IL-17 in the prostate anterior lobe in TRAMP mice. TISSUE & CELL, v. 50, p. 96-103, FEB 2018. (15/16747-3)